ZyVersa net loss narrows 53.9% to $1.79 million in Q1 FY26

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics, Inc. - Common Stock

ZVSA

0.00
  • ZyVersa Therapeutics posted a net loss of USD 1.79 million for the quarter ended March 31, 2026, narrowing 53.9% from a year earlier.
  • Operating loss narrowed 39.2% to USD 1.31 million, with research and development expense down 77.6% to USD 58,000.
  • General and administrative expense fell 33.9% to USD 1.25 million, while other expense rose to USD 489,000.
  • Cash and cash equivalents totaled USD 300,000 at March 31, 2026, with working capital deficit widening to USD 14.13 million.
  • Management said cash on hand is expected to fund operations on a month-to-month basis, with substantial doubt about ability to continue as a going concern for 12 months after issuance of financial statements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zyversa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022759), on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.